Table 1.

First-line treatment resource use according to expert panel

Resource usagea	Mean values reported by the expert panel
	DAPTO	LINE	TEICO	TIGE	VANCO
No. of days of treatmentb	9.8	9.2	11.5	11.7	11.8
No. of days in hospitalc	10.3	9.2	14.0	13.0	12.5
No of days IV	9.8	6.7	12	11.7	11.8
Average daily dose (mg)d	458	1,200	500	133	2,000
IV doses per day	1.0	2.0	1.0	2.0	2.0
No. of days oral	0.0	2.5	0.0	0.0	0.0
Oral doses per day	0.0	2.0	0.0	0.0	0.0
Additional no. of days in hospital due to AE	5	5	5	5	5
Additional no. of days in hospital due to treatment failure	7	7	7	7	7

AE adverse events, DAPTO daptomycin, IV intravenous, LINE linezolid, TEICO teicoplanin, TIGE tigecycline, VANCO vancomycin

^aValues are calculated as means of expert panel feedback

^bExcluding the treatment time prior to cultivation results

^cTime from hospital admission to discharge

^dEstimated for a ‘typical’ 75 kg patient